Deepti Saxena
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Deepti Saxena has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Shubha Rajendra Phadke
Department of Medical Genetics, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
10 shared publications Amita Moirangthem
Department of Medical Genetics SGPGIMS Lucknow India
4 shared publications- Amita Moirangthem
Department of Medical Genetics Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow India
4 shared publications Arya Shambhavi
Department of Medical Genetics, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
4 shared publicationsHaseena Sait
Department of Medical Genetics SGPGIMS Lucknow India
3 shared publicationsAmit K. Tiwari
Department of Medical Genetics, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, 226014, Uttar Pradesh, India
2 shared publications
Latest Publications
- 12 July 2025
- Published by Wiley in Clinical Genetics
- Vol. 108 (6) , 684-695
Molecular and Clinical Landscape of Osteogenesis Imperfecta: Unraveling Autosomal Recessive Forms, Therapeutic Outcomes, and Bone Mineral Density in Carriers
Osteogenesis imperfecta (OI) is a heritable disorder characterized by bone fragility and marked genetic and phenotypic heterogeneity. This study explores the molecular and clinical spectrum of OI, with a focus on autosomal recessive (AR) forms, therapeutic outcomes, and bone mineral density (BMD) in carriers of AR OI‐associated gene variants from the Indian population. A total of 78 clinically suspected OI patients were analyzed, yielding a high diagnostic rate of 92.3%. Exome sequencing was performed in all cases, with whole‐genome sequencing in selected exome‐negative cases. Autosomal dominant (AD) and AR OI accounted for 66% and 34% of cases, respectively. P3H1 ( n = 11) was the most frequently implicated AR gene causing OI, followed by SERPINF1 ( n = 5) and WNT1 ( n = 4), with 79% of AR variants being novel. Phenotypic evaluation ( n = 67) revealed fractures, short stature (87%), and bony deformities (84%) as predominant features. A rare homozygous COL1A1 variant was identified in one patient, while another patient harbored additional variants in AD OI genes, suggesting a potential digenic or modifier effect. Phenotypic severity followed the order from most to least severe: AR genes > COL1A2 (substitution and non‐substitution) > COL1A1 (substitution > non‐substitution). A self‐designed, preliminary clinical severity scoring system ranked CRTAP followed by P3H1, as the AR genes associated with the most severe phenotypes. Therapeutic assessment showed a significant reduction in fracture incidence following zoledronate therapy only in the COL1A1 group, with no notable improvements in the COL1A2 or AR groups. Additionally, BMD evaluation in carrier parents of AR gene causing OI indicated a higher predisposition to low BMD among WNT1 gene carriers. However, these findings are preliminary and limited by small sample size. This study provides an extensive genotypic and phenotypic characterization of OI in the Indian population, with a focus on AR OI. It documents differential therapeutic responses among genetic subgroups and provides preliminary observations on BMD in carrier parents of AR OI—an aspect that has been less explored previously and suggest the need for tailored management strategies. The findings in this study also raise the possibility of genetic modifiers contributing to phenotypic variability, warranting further investigation.
- 12 July 2025
- Published by Wiley in Clinical Genetics
- Vol. 108 (6) , 684-695
Molecular and Clinical Landscape of Osteogenesis Imperfecta: Unraveling Autosomal Recessive Forms, Therapeutic Outcomes, and Bone Mineral Density in Carriers
Osteogenesis imperfecta (OI) is a heritable disorder characterized by bone fragility and marked genetic and phenotypic heterogeneity. This study explores the molecular and clinical spectrum of OI, with a focus on autosomal recessive (AR) forms, therapeutic outcomes, and bone mineral density (BMD) in carriers of AR OI‐associated gene variants from the Indian population. A total of 78 clinically suspected OI patients were analyzed, yielding a high diagnostic rate of 92.3%. Exome sequencing was performed in all cases, with whole‐genome sequencing in selected exome‐negative cases. Autosomal dominant (AD) and AR OI accounted for 66% and 34% of cases, respectively. P3H1 ( n = 11) was the most frequently implicated AR gene causing OI, followed by SERPINF1 ( n = 5) and WNT1 ( n = 4), with 79% of AR variants being novel. Phenotypic evaluation ( n = 67) revealed fractures, short stature (87%), and bony deformities (84%) as predominant features. A rare homozygous COL1A1 variant was identified in one patient, while another patient harbored additional variants in AD OI genes, suggesting a potential digenic or modifier effect. Phenotypic severity followed the order from most to least severe: AR genes > COL1A2 (substitution and non‐substitution) > COL1A1 (substitution > non‐substitution). A self‐designed, preliminary clinical severity scoring system ranked CRTAP followed by P3H1, as the AR genes associated with the most severe phenotypes. Therapeutic assessment showed a significant reduction in fracture incidence following zoledronate therapy only in the COL1A1 group, with no notable improvements in the COL1A2 or AR groups. Additionally, BMD evaluation in carrier parents of AR gene causing OI indicated a higher predisposition to low BMD among WNT1 gene carriers. However, these findings are preliminary and limited by small sample size. This study provides an extensive genotypic and phenotypic characterization of OI in the Indian population, with a focus on AR OI. It documents differential therapeutic responses among genetic subgroups and provides preliminary observations on BMD in carrier parents of AR OI—an aspect that has been less explored previously and suggest the need for tailored management strategies. The findings in this study also raise the possibility of genetic modifiers contributing to phenotypic variability, warranting further investigation.
- 30 April 2025
- Published by Wiley in Clinical Genetics
- Vol. 108 (4) , 422-432
Spectrum of Inherited Childhood‐Onset Dystonia: Case Series of 19 Families With Genotype and Phenotype Characterization Highlighting the Treatable Causes
Childhood‐onset dystonia, a clinically and genetically diverse group of disorders, can be challenging to diagnose. Information on the genotype and phenotype spectrum in the Indian population is limited. This study reports the clinical and molecular findings of monogenic childhood‐onset dystonia in 22 individuals from 19 Indian families. Complex dystonia was the most frequent type, followed by combined and isolated forms. A total of 23 variants across 17 genes were identified, including nine novel ones. These disorders include four autosomal dominant, one X‐linked recessive, one mitochondrial, and the remaining 11 autosomal recessive conditions. Five potentially treatable disorders were identified, and treatment was initiated in three families, showing satisfactory responses, particularly in dopa‐responsive dystonias. Our study contributes four additional genes—CYP27A1, NDUFAF3, FUCA1, and FIG4—to the list of genes associated with complex dystonia. Exome sequencing proved crucial in diagnosing the etiology of dystonia, identifying treatable forms, and aiding genetic counseling. This study emphasizes the significance of using NGS for early genetic diagnosis to enable timely targeted therapies, offer precise genetic counseling to families, and prevent recurrence in the family.
- 30 April 2025
- Published by Wiley in Clinical Genetics
- Vol. 108 (4) , 422-432
Spectrum of Inherited Childhood‐Onset Dystonia: Case Series of 19 Families With Genotype and Phenotype Characterization Highlighting the Treatable Causes
Childhood‐onset dystonia, a clinically and genetically diverse group of disorders, can be challenging to diagnose. Information on the genotype and phenotype spectrum in the Indian population is limited. This study reports the clinical and molecular findings of monogenic childhood‐onset dystonia in 22 individuals from 19 Indian families. Complex dystonia was the most frequent type, followed by combined and isolated forms. A total of 23 variants across 17 genes were identified, including nine novel ones. These disorders include four autosomal dominant, one X‐linked recessive, one mitochondrial, and the remaining 11 autosomal recessive conditions. Five potentially treatable disorders were identified, and treatment was initiated in three families, showing satisfactory responses, particularly in dopa‐responsive dystonias. Our study contributes four additional genes—CYP27A1, NDUFAF3, FUCA1, and FIG4—to the list of genes associated with complex dystonia. Exome sequencing proved crucial in diagnosing the etiology of dystonia, identifying treatable forms, and aiding genetic counseling. This study emphasizes the significance of using NGS for early genetic diagnosis to enable timely targeted therapies, offer precise genetic counseling to families, and prevent recurrence in the family.
- 20 November 2023
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 66 (12) , 104888
Resolving fetal hydrops – A rare entity
- 20 November 2023
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 66 (12) , 104888
Resolving fetal hydrops – A rare entity
- 17 October 2023
- Published by Wiley in Clinical Genetics
- Vol. 105 (2) , 226-227
Variants in DOK7 results in fetal akinesia deformation sequence: A case report and review of literature
We report the third case of FADS due to biallelic DOK7 variants, which further strengthens the association of DOK7 with this lethal phenotype and lack of genotype phenotype correlation.
- 17 October 2023
- Published by Wiley in Clinical Genetics
- Vol. 105 (2) , 226-227
Variants in DOK7 results in fetal akinesia deformation sequence: A case report and review of literature
We report the third case of FADS due to biallelic DOK7 variants, which further strengthens the association of DOK7 with this lethal phenotype and lack of genotype phenotype correlation.
- 3 April 2023
- Published by Wiley in Prenatal Diagnosis
- Vol. 43 (5) , 579-595
Retrospective diagnosis by parental testing in the next generation sequencing era and utility of reanalysis of exome data
Objective: Genetic diseases are an important cause of neonatal and childhood mortality. For couples with a history of demise of previous children, screening for carrier status can be done by exome sequencing (ES) of the parents. Our aim was to describe the clinical utility of “targeted parental ES” in such couples and to assess the utility of reanalysis of parental ES data.Method: We analyzed previous records, including ES reports, of 52 families with demise of previous offspring with a suspected genetic disorder. We also retrieved and reanalyzed raw data of parental ES in FASTQ format from the testing lab.Results: A potential diagnosis was obtained in 30/52 (57.7%) of couples. We found 38/70 (54.3%) novel variants in this cohort. Shared carrier status for more than one autosomal or X‐linked recessive disorder was identified in 18% of couples. Reanalysis of raw data resulted in a reclassification of variants in 15% of cases.Conclusion: Targeted parental ES can be helpful for families with demise of previous offspring with a suspected genetic disorder.
- 3 April 2023
- Published by Wiley in Prenatal Diagnosis
- Vol. 43 (5) , 579-595
Retrospective diagnosis by parental testing in the next generation sequencing era and utility of reanalysis of exome data
Objective: Genetic diseases are an important cause of neonatal and childhood mortality. For couples with a history of demise of previous children, screening for carrier status can be done by exome sequencing (ES) of the parents. Our aim was to describe the clinical utility of “targeted parental ES” in such couples and to assess the utility of reanalysis of parental ES data.Method: We analyzed previous records, including ES reports, of 52 families with demise of previous offspring with a suspected genetic disorder. We also retrieved and reanalyzed raw data of parental ES in FASTQ format from the testing lab.Results: A potential diagnosis was obtained in 30/52 (57.7%) of couples. We found 38/70 (54.3%) novel variants in this cohort. Shared carrier status for more than one autosomal or X‐linked recessive disorder was identified in 18% of couples. Reanalysis of raw data resulted in a reclassification of variants in 15% of cases.Conclusion: Targeted parental ES can be helpful for families with demise of previous offspring with a suspected genetic disorder.
- Open Access
- 1 May 2022
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 15, 5133-5144
Integrated Management Strategies for Epidermolysis Bullosa: Current Insights
Epidermolysis bullosa (EB) is a group of rare genodermatoses that is characterized by skin fragility resulting from minor trauma. There are four major subtypes, namely, EB simplex, junctional EB, dystrophic EB and Kindler EB, depending upon the localization of defective protein and resulting plane of blister formation. The phenotype is heterogeneous in terms of severity and majority of them present at birth or neonatal period. Currently, the treatment is mainly supportive and requires multidisciplinary care. The complex molecular pathology creates difficulty in discovering a unified curative treatment approach. But with arduous efforts, significant progress has been made in the development of treatment strategies in the last decade. The management strategies range from targeting the underlying causative factor to symptom-relieving approaches, and include gene, mRNA, protein, cell and combination therapies. In this review, we enumerate the promising approaches that are currently under various stages of investigation to provide effective treatment for patients with EB.
- 1 May 2022
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 15, 5133-5144
Open AccessIntegrated Management Strategies for Epidermolysis Bullosa: Current Insights
Epidermolysis bullosa (EB) is a group of rare genodermatoses that is characterized by skin fragility resulting from minor trauma. There are four major subtypes, namely, EB simplex, junctional EB, dystrophic EB and Kindler EB, depending upon the localization of defective protein and resulting plane of blister formation. The phenotype is heterogeneous in terms of severity and majority of them present at birth or neonatal period. Currently, the treatment is mainly supportive and requires multidisciplinary care. The complex molecular pathology creates difficulty in discovering a unified curative treatment approach. But with arduous efforts, significant progress has been made in the development of treatment strategies in the last decade. The management strategies range from targeting the underlying causative factor to symptom-relieving approaches, and include gene, mRNA, protein, cell and combination therapies. In this review, we enumerate the promising approaches that are currently under various stages of investigation to provide effective treatment for patients with EB.
- 6 January 2022
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 188 (4) , 1317-1322
Monosomy 1p36: Report of a cohort of 13 Asian Indian patients
Monosomy 1p36 is one of the common microdeletion syndromes with a recognizable facial phenotype. Failure to thrive, developmental delay, congenital heart disease, and other abnormalities are common in these patients. This is the first study on Asian Indian patients with monosomy 1p36, documenting the phenotypic characteristics of 13 patients, indicating phenotypic similarities in a diverse population and broadening the clinical spectrum.
- 6 January 2022
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 188 (4) , 1317-1322
Monosomy 1p36: Report of a cohort of 13 Asian Indian patients
Monosomy 1p36 is one of the common microdeletion syndromes with a recognizable facial phenotype. Failure to thrive, developmental delay, congenital heart disease, and other abnormalities are common in these patients. This is the first study on Asian Indian patients with monosomy 1p36, documenting the phenotypic characteristics of 13 patients, indicating phenotypic similarities in a diverse population and broadening the clinical spectrum.
- 1 December 2021
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 64 (12) , 104345
Novel pathogenic variants in an Indian cohort with epidermolysis bullosa: Expanding the genotypic spectrum
- 1 December 2021
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 64 (12) , 104345
Novel pathogenic variants in an Indian cohort with epidermolysis bullosa: Expanding the genotypic spectrum
- 29 September 2021
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 44 (1) , 186-192
Molecular analysis of severe hemophilia B in Indian families: Identification of mutational hotspot and novel variants
Introduction: Hemophilia B is associated with molecular heterogeneity, with more than 1200 unique variants in the F9 gene. We hereby describe the mutational spectrum of severe hemophilia B patients presenting in a tertiary‐care center in India.Method: DNA was extracted from peripheral blood samples of 35 diagnosed severe hemophilia B patients belonging to 32 families, and were subjected to Sanger sequencing. Determination of the effect of novel variants on the protein structure and correlation between genotype and phenotype was attempted using in‐silico tools.Results: Twenty‐seven different mutations were detected in 30 probands, including 20 known and 7 novel variants. Also, we found one suspected case of whole gene deletion. The serine peptidase domain harbored most of the variants (48.1%). Inhibitory antibodies were found in two patients.Conclusions: This study provides a comprehensive mutational spectrum and mutation screening strategy by Sanger sequencing of F9 gene in severe hemophilia B patients, in a resource‐constraint setting.
- 29 September 2021
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 44 (1) , 186-192
Molecular analysis of severe hemophilia B in Indian families: Identification of mutational hotspot and novel variants
Introduction: Hemophilia B is associated with molecular heterogeneity, with more than 1200 unique variants in the F9 gene. We hereby describe the mutational spectrum of severe hemophilia B patients presenting in a tertiary‐care center in India.Method: DNA was extracted from peripheral blood samples of 35 diagnosed severe hemophilia B patients belonging to 32 families, and were subjected to Sanger sequencing. Determination of the effect of novel variants on the protein structure and correlation between genotype and phenotype was attempted using in‐silico tools.Results: Twenty‐seven different mutations were detected in 30 probands, including 20 known and 7 novel variants. Also, we found one suspected case of whole gene deletion. The serine peptidase domain harbored most of the variants (48.1%). Inhibitory antibodies were found in two patients.Conclusions: This study provides a comprehensive mutational spectrum and mutation screening strategy by Sanger sequencing of F9 gene in severe hemophilia B patients, in a resource‐constraint setting.